Top Market Research Companies in New Zealand (2026 Guide)

New Zealand is a strategically distinct pharmaceutical market, with a combined pharma and healthcare market estimated at approximately NZD 6 billion in 2026. Commercial success in New Zealand depends on navigating Medsafe regulatory approval, PHARMAC health technology assessment, and Health New Zealand Te Whatu Ora engagement — all while meeting the evidence standards applied by PHARMAC's 9-factor Factors for Consideration framework in its Pharmaceutical Schedule listing decisions.

New Zealand pharmaceutical market research in 2026 is shaped by three defining dynamics:

• PHARMAC Factors for Consideration rigour: PHARMAC applies a 9-factor framework — including need, health benefits, cost and cost-effectiveness, and consistency with government priorities — to Pharmaceutical Schedule listing decisions. Unlike Australia's PBAC QALY-threshold model, PHARMAC operates with a fixed budget and applies a comparative ranking approach. Market researchers must design evidence aligned to PHARMAC's specific methodology rather than simply adapting PBAC, NICE, or CADTH submission frameworks.
• Medsafe and PHARMAC sequencing: Medsafe grants marketing authorisation independently of TGA — unlike Australia's TGA-reliance pathway, NZ requires its own Medsafe registration. PHARMAC then evaluates Pharmaceutical Schedule listing separately. The gap between Medsafe approval and Schedule listing creates a period requiring manufacturer-funded access programs and pre-submission market research to optimise PHARMAC evidence packages.
• Health New Zealand Te Whatu Ora regional complexity: Health New Zealand Te Whatu Ora administers 16 health regions following the 2022 restructuring of DHBs. Regional health networks and hospital formulary committees, alongside private health insurers (Southern Cross, nib NZ, AIA) and the Accident Compensation Corporation (ACC), form the key secondary payer and access audiences requiring dedicated New Zealand market research.

New Zealand KOL mapping requires tracking influence across a compact but clinically significant academic medical centre landscape. Auckland institutions (Auckland City Hospital, Middlemore Hospital, North Shore Hospital) hold strong guideline and publication influence in oncology, haematology, cardiovascular, and transplant; Christchurch Hospital (Canterbury region) combines academic prominence with large trial enrolment volumes in oncology, respiratory, and general medicine; Wellington Regional Hospital and Hutt Hospital lead in government health policy influence and access to PHARMAC-adjacent clinical advisors; and Dunedin Hospital and Waikato Hospital provide regional academic reach across the South Island and Waikato-Bay of Plenty. Effective NZ KOL mapping segments influence by region, institution, therapy area, and Pharmaceutical Schedule advisory involvement.

New Zealand payer research requires access to PHARMAC decision-makers, Factors for Consideration advisors, and Health New Zealand Te Whatu Ora formulary stakeholders — the most commercially important respondents in NZ pharmaceutical research. Payer interviews cover Pharmaceutical Schedule listing preferences, PHARMAC budget constraints, cost-utility evidence expectations, private insurer coverage dynamics, and ACC procurement criteria. BioNixus conducts national PHARMAC payer and private insurer interviews as dedicated payer research programs.

BioNixus conducts KOL mapping and payer research across New Zealand in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our New Zealand pharmaceutical market research guide and top healthcare market research companies in New Zealand for details.